Ex parte VOSS et al. - Page 11




          Appeal No. 1997-3094                                                        
          Application 08/405,279                                                      


          novel characteristics of appellants’ claimed invention.                     
               Appellants argue that the presence of up to 0.5 g/ft  of3                  
          platinum unexpectedly causes suppression of the oxidation of                
          SO  to SO  (brief, page 19), and that no evidence of unexpected2     3                                                                   
          results is needed because it would have been unexpected that                
          appellants’ catalytic material has any of the recited                       
          catalytic activity (reply brief, pages 3-4).  This argument is              
          not persuasive because Wan teaches that high surface area                   
          ceria is believed to serve as a promoter for oxidation-                     
          reduction reactions (Col. 8, lines 11-13) and can either                    
          provide a synergistic effect to the platinum group metal                    
          catalytic component (col. 8, lines 13-15) or can be used in                 
          the absence of a platinum group metal catalytic component                   
          (abstract, first sentence).  Thus, it reasonably appears that               
          one of ordinary skill in the art would have expected                        
          appellants’ catalyst to have the recited activity.  The claims              
          do not require suppression of the oxidation of SO .  To show                
                                                           2                          
          unexpected results, appellants must provide evidence in the                 
          form of a comparison of appellants’ claimed invention with the              
          closest prior art, see In re Baxter Travenol Labs., 952 F.2d                


                                          11                                          





Page:  Previous  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  Next 

Last modified: November 3, 2007